Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP -99.50% 3-Year Book Growth Rate is 49.00% as of Jun. 2026, which is 21% above its 10-year median of 40.50. The stock has 8 warning signs investors should review. Among 1,129 Biotechnology companies, Regen BioPharma ranks better than 93.89% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was 49.00% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 44.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 26.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Regen BioPharma was 60.60% per year. The lowest was -283.90% per year. And the median was 40.50% per year.
Regen BioPharma (OTCPK:RGBP) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Regen BioPharma 3-Year Book Growth Rate Related Terms
RGBP vs IOBTQ, SCPX, LIPO: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Regen BioPharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's 3-Year Book Growth Rate falls into.
Regen BioPharma 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 49.00% mean?
Regen BioPharma (RGBP) has a 3-Year Book Growth Rate of 49.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Regen BioPharma and its competitors. This is 21% above median its historical median of 40.50. According to the industry distribution chart, Regen BioPharma ranks #69 out of 1129 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Regen BioPharma's 3-Year Book Growth Rate too high?
Regen BioPharma's current 3-Year Book Growth Rate of 49.00% is 21% above median its 10-year median of 40.50. Based on the distribution chart, Regen BioPharma ranks #69 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Regen BioPharma's 3-Year Book Growth Rate compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #69 out of 1129 companies for 3-Year Book Growth Rate. This places Regen BioPharma in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Regen BioPharma and its competitors. Regen BioPharma's current 3-Year Book Growth Rate is 49.00%, which is 21% above median its own 10-year median of 40.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 98% below its estimated fair value. The current 3-Year Book Growth Rate is 49.00%, which is 21% above median its 10-year median of 40.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 3-Year Book Growth Rate is 49.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
